TNFSF11 and neoplasm: In addition, denosumab, targeting the receptor activation of nuclear factor kappa-β ligand (RANKL), reduces fracture risks in tumor metastases and showed a 99% inhibition in giant bone cell tumor progression in Phase II studies (96, 97).